Actively Recruiting
Study of Stereotactic Body Radiation Therapy with Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer
Led by Istituto Clinico Humanitas · Updated on 2025-07-30
49
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Prostate Cancer is a common cancer in men worldwide, with many cases diagnosed early enough for potentially curative treatment. This research focuses on high-risk localized prostate cancer, exploring the safety and effectiveness of combining Stereotactic Body Radiation Therapy SBRT with Androgen Deprivation Therapy ADT. The study builds on previous trials that showed SBRT can be a valid alternative to conventional radiation, especially for unfavorable prostate cancer cases. Participants will receive SBRT at a dose of 40 Gy in 5 fractions given every other day, alongside ADT with relugolix for 18 to 24 months as part of their clinical care. This observational study will monitor patients receiving this combination treatment to evaluate its outcomes and safety in managing high-risk prostate cancer confined to the prostate. During the study, researchers will assess biochemical relapse-free survival over two and five years, along with distant metastases-free survival and cancer-specific survival. They will also collect biomarker data such as circulating tumor DNA, and use quality of life questionnaires and symptom scores related to urinary and sexual function. Participants will be followed regularly with blood tests measuring PSA and testosterone levels, with total follow-up extending up to five years to monitor treatment effects and safety.
CONDITIONS
Brief Title
PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here